查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012315

次世代定序市场：依技术、产品类型、工作流程、最终用户和应用划分－2026-2032年全球市场预测

Next Generation Sequencing Market by Technology, Product Type, Workflow, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计次世代定序市场在 2025 年的价值为 266.9 亿美元，在 2026 年增长至 317.7 亿美元，到 2032 年达到 1257.8 亿美元，复合年增长率为 24.78%。

主要市场统计数据
基准年 2025 266.9亿美元
预计年份：2026年 317.7亿美元
预测年份 2032 1257.8亿美元
复合年增长率 (%) 24.78%

将技术进步和临床应用与营运重点和相关人员决策连结起来的次世代定序策略方法。

次世代定序(NGS) 已从一项小众实验室技术发展成为塑造生物医学研究、诊断和生物製药创新的基础平台。本文概述了 NGS 的技术成熟度、不断扩展的临床应用以及决策者为有效利用 NGS 所必须应对的营运挑战。定序化学、仪器处理能力和生物资讯工具集的进步降低了技术门槛。同时，NGS 在肿瘤学、感染疾病监测和罕见疾病遗传学等领域的实际临床应用也展现出实际的临床效用。同时，随着定序资料在患者照护和治疗方法开发中的应用日益广泛，各机构也面临着对资料品质、互通性和合规性日益增长的期望。

技术、分析和监管趋势的融合正在重新定义定序能力、检验预期和协作部署模式。

次世代定序技术正经历着一场变革性的转变，多种因素共同作用，重塑其功能和应用。首先，仪器创新持续提升速度、准确性和成本效益，从而催生了新的应用场景，例如快速识别感染疾病病原体和肿瘤即时检验。其次，生物资讯学正从客製化脚本转向日益标准化和验证的流程，这些流程整合了比对、註释和变异检测，能够提供适用于临床报告的可重复结果。这些调查方法的进步降低了检查室间的差异，缩短了结果获取时间，从而增强了下一代提案的临床和商业性价值。

2025 年的关税措施将如何改变检查室和服务供应商的序列供应链、采购实务和业务永续营运策略？

美国2025年实施的关税措施对次世代定序的价值链、筹资策略和成本管理实务产生了多方面的影响，但并未改变基因组技术的基本科学价值。关税增加了进口成本，影响了仪器、试剂和配件的流通，促使各机构重新评估其供应商多元化策略。因此，采购团队加快了对区域供应商的选择流程，并寻求签订长期合约以稳定价格和供应。同时，製造商和经销商调整了库存策略，维持更大的缓衝库存，并重新评估製造地，以降低关税相关中断的风险。

策略性投资以综合細項分析为指导，该分析将技术类型、产品类型、工作流程阶段、最终用户画像和应用主导的优先顺序连结起来。

关键的市场区隔洞察揭示了技术优势与工作流程需求的交汇点，从而确定了实施和功能优先顺序。基于技术，市场涵盖扩增子定序、基因组定序、RNA定序、标靶定序、全EXOME子定序 (WES) 和全基因组定序 (WGS)，每种技术在深度、广度和临床效用方面各有侧重，指南平台和检测方法的选择。基于产品类型，产品分为耗材和试剂、仪器以及软体和服务。在耗材和试剂中，重点关注酵素和试剂盒；在仪器中，区分了定序仪和辅助仪器；软体和服务则细分为资料分析软体和服务，反映了检验分析和受控解读日益增长的重要性。

影响美洲、欧洲、中东、非洲和亚太地区定序应用、监管协调和基础设施投资的区域发展趋势。

区域趋势持续影响次世代定序技术在各类医疗保健系统、研究网路和商业生态系统中的部署和扩展。在美洲，应用趋势凸显了临床诊断、肿瘤学应用以及由先进的生物资讯学提供者和云端原生储存解决方案支援的强大诊断服务市场。北美学术机构和生物技术中心正积极推动方法检验和转化研究，而商业实验室网路则专注于检测标准化和高通量工作流程。

竞争生态系统分析揭示了仪器製造商、试剂供应商、分析供应商和服务实验室如何合作提供整合定定序价值提案。

定序生态系中的竞争格局是仪器製造商、试剂供应商、软体和分析服务提供者以及服务实验室相互交织的产物，它们各自追求独特的价值提案。领先的仪器供应商专注于通量、准确性和整合工作流程解决方案，而试剂和试剂盒供应商则强调可靠性、批间一致性和符合法规要求的文檔，以满足临床检验需求。软体和服务供应商则透过检验的分析流程、解读内容和託管服务来减轻检查室和临床医生的分析负担，从而实现差异化竞争。

为领导者提供实用的策略指导，以协调技术选择、资料基础设施、供应链弹性和伙伴关係模式，从而负责任地定序规模。

我们为产业领导者提供的切实可行的建议着重于协调技术选择、营运设计和伙伴关係策略，以最大限度地发挥定序的潜力，同时管控与检验、供应链和资料管治相关的风险。首先，优先考虑模组化和检验的工作流程，以实现分阶段扩展。选择标准化的分析流程、可互通的平台和耗材将缩短临床部署时间，并简化监管合规流程。其次，投资于混合资料架构，平衡云端扩充性和本地管理，以满足资料主权要求和对延迟敏感的临床应用情境。第三，制定供应商多元化策略和长期采购协议，以应对关税和中断风险，同时维持临床应用所需的品质和文件标准。

采用三角测量法的调查方法，结合对关键相关人员的访谈、检查室工作流程的基准测试以及与第二手资料的检验，对该序列产生了可靠的见解。

本报告的调查方法融合了对主要相关人员的访谈、检查室工作流程分析以及对二手资讯的严格检验，从而得出基于证据的结论。关键资讯来源包括对仪器工程师、临床实验室经理、生物资讯学经理和采购专家的访谈，以了解实际操作中的限制和创新重点。除这些定性研究外，还进行了结构化的工作流程观察和技术基准评估，重点关注样本製备、定序和分析各阶段的定序准确性、结果获取时间和整合挑战。

结论强调，检验的工作流程、稳健的营运结构和协作执行对于最大限度地发挥定序技术的临床和研究价值至关重要。

本执行摘要概述了次世代定序的策略现实。儘管技术进步拓展了其应用范围和临床意义，但与工作流程、数据和采购相关的营运复杂性阻碍了其有效实施。相关人员将定序视为一项系统性挑战，涵盖仪器选择、检验的耗材、可互通的分析以及稳健的供应链。随着监管机构日益重视检验和软体完整性，可重复的流程和完善的品管系统的重要性进一步凸显，而与关税相关的采购趋势则强调了多元化采购和与供应商建立策略合作关係的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章次世代定序市场：依技术划分

  • 扩增子序列
  • 基因panel定序
  • RNA定序
  • 目标序列
  • 全EXOME定序（WES）
  • 全基因组定序（WGS）

第九章：次世代定序市场：依产品类型划分

  • 耗材和试剂
    • 酵素
    • 成套工具
  • 装置
    • 相关设备
    • 序列器
  • 软体服务
    • 数据分析软体
    • 服务

第十章：次世代定序市场：依工作流程划分

  • 数据分析
    • 结盟
    • 註解
    • 变体调用
  • 资料网关
    • 云端储存
    • 本地储存
  • 样品製备
    • 样品製备
    • 模板准备
  • 定序

第十一章次世代定序市场：依最终用户划分

  • 学术研究机构
  • 医疗诊断检测机构
  • 製药和生物技术公司

第十二章次世代定序市场：按应用领域划分

  • 农业基因组学
  • 携带者筛检
  • 表观基因
  • 法医学基因组学
  • 遗传性疾病和罕见疾病
  • 感染疾病
  • 神经基因组学
  • 肿瘤学
  • 药物基因体学

第十三章次世代定序市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章次世代定序市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章次世代定序市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国次世代定序市场

第十七章：中国的次世代定序市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Azenta US, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics
  • GenScript
  • Hamilton Company
  • Illumina, Inc.
  • Invitae Corporation
  • LGC Limited
  • Macrogen Inc.
  • Merck KGaA
  • MGI Tech Co., Ltd.
  • NeoGenomics Laboratories
  • Novogene Co., Ltd.
  • Oxford Nanopore Technologies Plc.
  • Pacific Biosciences of California, Inc.
  • QIAGEN NV
  • Revvity
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4312A385A68A

The Next Generation Sequencing Market was valued at USD 26.69 billion in 2025 and is projected to grow to USD 31.77 billion in 2026, with a CAGR of 24.78%, reaching USD 125.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 26.69 billion
Estimated Year [2026] USD 31.77 billion
Forecast Year [2032] USD 125.78 billion
CAGR (%) 24.78%

A strategic orientation to next generation sequencing that ties technological advances and clinical adoption to operational priorities and stakeholder decision-making

Next generation sequencing (NGS) has transitioned from a niche laboratory technique to a foundational platform shaping biomedical research, diagnostics, and biopharmaceutical innovation. This introduction outlines the technological maturation, broadening clinical applications, and operational challenges that decision-makers must reconcile to harness NGS effectively. Advances in sequencing chemistry, instrument throughput, and bioinformatic toolsets have lowered technical barriers, while real-world deployments in oncology, infectious disease surveillance, and rare disease genetics demonstrate tangible clinical utility. At the same time, organizations face rising expectations for data quality, interoperability, and regulatory compliance as sequencing data increasingly informs patient care and therapeutic development.

Understanding the current landscape requires attention to the interplay between technology evolution and user needs. Laboratories seek reproducible workflows that balance throughput with accuracy, clinicians demand actionable reports that integrate into electronic health record systems, and developers of therapeutics rely on high-fidelity genomic data for biomarker discovery and patient stratification. Consequently, infrastructure considerations such as data storage, scalable compute, and robust analysis pipelines have become as important as instrument selection. As adoption deepens, strategic stakeholders must evaluate not only immediate performance metrics but also long-term operational costs, vendor roadmaps, and ecosystem partnerships.

This summary sets the scene for subsequent sections by emphasizing that NGS is now a systems-level investment. Effective deployment hinges on aligning technical capabilities with workflow requirements and patient-centric outcomes, while adapting to evolving regulatory expectations and global supply chain dynamics.

Converging technological, analytical, and regulatory trends that are redefining sequencing capabilities, validation expectations, and collaborative deployment models

The landscape of next generation sequencing is undergoing transformative shifts driven by multiple converging forces that reshape both capability and adoption. First, instrument innovation continues to prioritize speed, accuracy, and cost-efficiency, enabling new use cases such as rapid infectious disease pathogen identification and real-time oncology monitoring. Second, bioinformatics has shifted from bespoke scripts to increasingly standardized, validated pipelines that incorporate alignment, annotation, and variant calling with reproducible outputs suitable for clinical reporting. These methodological advances reduce variability between laboratories and accelerate time-to-result, which in turn amplifies the clinical and commercial value proposition of NGS.

Concurrently, data management and storage paradigms have evolved; stakeholders increasingly adopt hybrid architectures that combine cloud storage with on-premise compute to reconcile data sovereignty, latency, and security concerns. Integration with electronic health records and clinical decision support tools is becoming more seamless, enabling genomic insights to inform point-of-care decisions. Regulatory frameworks are adapting to this reality, with a stronger focus on analytical and clinical validation, software-as-a-medical-device considerations, and the provenance of reference data sets. Finally, collaboration models are shifting as partnerships between academic centers, diagnostic labs, and biopharma accelerate co-development of assays and companion diagnostics. Together, these shifts create a dynamic environment where technical innovation, validation rigor, and ecosystem partnerships jointly determine the rate and scope of NGS adoption.

How 2025 tariff measures reshaped sequencing supply chains, procurement behaviors, and operational resilience strategies across laboratories and service providers

The introduction of tariffs by the United States in 2025 has exerted a multifaceted influence on next generation sequencing supply chains, procurement strategies, and cost-management practices without altering the underlying scientific value of genomic technologies. Tariff measures affected the flow of instruments, reagents, and ancillary components by increasing landed costs for imported items and prompting organizations to re-evaluate supplier diversification. As a result, procurement teams accelerated vendor qualification processes for regional suppliers and sought longer-term contracts to stabilize pricing and supply commitments. In parallel, manufacturers and distributors adjusted inventory strategies, maintaining higher buffer stocks and revisiting manufacturing footprints to mitigate the risk of tariff-related disruptions.

Operationally, laboratories and service providers adapted by optimizing reagent utilization, consolidating orders, and negotiating bundled service agreements that absorb some tariff-driven cost pressures. For institutions prioritizing clinical continuity, the emphasis shifted toward validated local sourcing and strengthened service-level agreements to ensure instrument uptime. Furthermore, the tariff environment prompted a reassessment of capital allocation timelines: organizations weighed the benefits of acquiring new high-throughput sequencers against incremental import costs and potential delays. At the same time, regulatory compliance and quality control requirements remained non-negotiable, driving investments in workflow efficiencies that preserve analytical performance even as procurement dynamics change. In essence, the cumulative effect of tariffs in 2025 accelerated supply-chain resilience planning and reinforced the importance of integrated procurement and operational strategies to sustain sequencing programs.

Integrated segmentation analysis that aligns technology types, product categories, workflow stages, end-user profiles, and application-driven priorities to guide strategic investment

Key segmentation insights reveal where technological strengths and workflow demands intersect to shape adoption and capability priorities. Based on Technology, the landscape spans Amplicon Sequencing, Gene Panel Sequencing, RNA Sequencing, Targeted Sequencing, Whole Exome Sequencing (WES), and Whole Genome Sequencing (WGS), each offering a distinct balance of depth, breadth, and clinical utility that informs platform and assay selection. Based on Product Type, offerings are organized across Consumables Reagents, Instruments, and Software Services; within Consumables Reagents the focus narrows to Enzymes and Kits, while Instruments distinguish Ancillary Instruments from Sequencers, and Software Services break down into Data Analysis Software and Services, reflecting the rising importance of validated analytics and managed interpretation.

Based on Workflow, critical stages include Data Analysis, Data Storage, Sample Preparation, and Sequencing; Data Analysis further segments into Alignment, Annotation, and Variant Calling, Data Storage differentiates Cloud Storage from On-Premise Storage, and Sample Preparation separates Library Preparation from Template Preparation, underscoring that bottlenecks can occur at multiple touchpoints beyond the sequencer itself. Based on End User, adoption patterns differ among Academic Research Institutes, Healthcare Diagnostic Laboratories, and Pharmaceutical Biotechnology Companies, each of which prioritizes different performance metrics, regulatory rigor, and scale considerations. Based on Application, deployments range across Agrigenomics, Carrier screening, Epigenomics, Forensic Genomics, Genetic & Rare Diseases, Infectious Diseases, Neurogenomics, Oncology, and Pharmacogenomics, demonstrating that application-specific requirements drive assay design, data interpretation needs, and downstream clinical or commercial pathways.

Taken together, these segmentation lenses show that strategic investments should align technology choice with specific workflow pinch points and end-user requirements, while emphasizing interoperable analysis and storage solutions that accommodate diverse applications and validation needs.

Regional deployment dynamics that influence sequencing adoption, regulatory alignment, and infrastructure investments across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape how next generation sequencing capabilities roll out and scale across different health systems, research networks, and commercial ecosystems. In the Americas, deployment trends emphasize clinical diagnostics, oncology applications, and a robust diagnostics services market supported by advanced bioinformatics providers and cloud-native storage solutions. North American academic centers and biotech hubs drive method validation and translational research, while commercial lab networks focus on assay standardization and high-throughput workflows.

In Europe, Middle East & Africa, regulatory harmonization, data protection frameworks, and diverse healthcare reimbursement models influence adoption cadence. European research consortia and national public health initiatives frequently collaborate to establish reference standards, while regional manufacturers and service providers respond to varying data sovereignty requirements by offering localized storage and compute options. Emerging hubs in the Middle East and North Africa are investing in sequencing capacity for public health surveillance and precision medicine pilot programs.

Across Asia-Pacific, growth patterns reflect a mix of government-led sequencing initiatives, expansive clinical sequencing adoption in select markets, and strong manufacturing capabilities for instruments and reagents. Several countries prioritize genomics for population health, infectious disease surveillance, and agriculture, prompting significant investments in laboratory infrastructure and workforce training. In each region, the balance of public and private funding, regulatory pathways, and local academic-industry collaborations determines how sequencing technologies are integrated into broader healthcare and research agendas.

Competitive ecosystem analysis revealing how instrument makers, reagent suppliers, analytics vendors, and service laboratories converge to offer integrated sequencing value propositions

Competitive positioning in the sequencing ecosystem reflects a blend of instrument manufacturers, reagent suppliers, software and analytics providers, and service laboratories, each pursuing distinct value propositions. Leading instrument providers concentrate on throughput, accuracy, and integrated workflow solutions, while reagent and kit suppliers emphasize reliability, lot-to-lot consistency, and regulatory-ready documentation to meet clinical validation needs. Software and services vendors differentiate through validated analysis pipelines, interpretive content, and managed services that reduce the interpretive burden on laboratories and clinicians.

Service laboratories and contract research organizations play a complementary role by offering scalable sequencing capacity, assay development partnerships, and decentralized testing models that allow clinical and research customers to access advanced capabilities without immediate capital investment. Strategic partnerships and licensing deals increasingly blur traditional vendor boundaries, as companies combine hardware, consumables, and analytic services into cohesive offerings that accelerate end-to-end validation. In response, purchasers evaluate vendors not only on instrument specifications but also on ecosystem support, data portability, and long-term roadmap commitments that ensure compatibility with evolving clinical standards and bioinformatic requirements.

Practical strategic guidance for leaders to align technology selection, data infrastructure, supply resilience, and partnership models to scale sequencing responsibly

Actionable recommendations for industry leaders focus on aligning technology selection, operational design, and partnership strategies to capture the full potential of sequencing while managing risks related to validation, supply chain, and data governance. First, prioritize modular and validated workflows that allow incremental scaling; selecting platforms and consumables that interoperate with standardized analysis pipelines reduces time-to-clinical-readiness and simplifies regulatory pathways. Second, invest in hybrid data architectures that balance cloud scalability with on-premise control to meet data sovereignty requirements and latency-sensitive clinical use cases. Third, develop supplier diversity strategies and longer-term procurement agreements that address tariff and supply disruption risks while preserving quality and documentation standards required for clinical use.

Additionally, cultivate strategic partnerships that extend beyond transactional procurement: co-development agreements with assay developers, data-sharing partnerships with academic centers, and managed service arrangements with analytics providers accelerate validation and broaden access. Upskilling laboratory staff in bioinformatics and quality systems is essential to maintain analytical rigor as workflows scale, and embedding interpretive expertise into clinical reports will improve clinician confidence and patient outcomes. Finally, regularly assess regulatory trajectories and engage with standards-setting bodies to ensure that internal validation programs and software development practices remain aligned with emerging guidance. These steps together create a resilient, scalable pathway from laboratory innovation to routine clinical impact.

A triangulated research methodology combining primary stakeholder interviews, laboratory workflow benchmarking, and secondary validation to produce robust sequencing insights

The research methodology underpinning this report synthesizes primary stakeholder interviews, laboratory workflow analyses, and rigorous secondary-source validation to ensure evidence-based conclusions. Primary inputs included consultations with instrument engineers, clinical laboratory directors, bioinformatics leaders, and procurement specialists to capture real-world constraints and innovation priorities. These qualitative engagements were complemented by structured workflow observations and technical benchmark assessments that focused on sequencing accuracy, time-to-result, and integration challenges across sample preparation, sequencing, and analysis stages.

Secondary validation incorporated peer-reviewed literature, regulatory guidance documents, and technology white papers to corroborate trends identified in primary research and to contextualize developments in bioinformatics and data management. Where applicable, comparative assessments of analytical pipelines-covering alignment, annotation, and variant calling-were performed to highlight reproducibility considerations and interpretive bottlenecks. The methodology emphasizes triangulation across data sources, transparency in assumptions, and clarity about the limits of inference, ensuring that findings are both actionable and grounded in a robust evidence base. Throughout, the approach maintained strict attention to data integrity, reproducibility, and the practical needs of laboratory and clinical stakeholders.

Concluding synthesis emphasizing that validated workflows, resilient operations, and collaborative execution unlock the full clinical and research value of sequencing technologies

This executive summary synthesizes the strategic realities of next generation sequencing: technological advances have expanded application breadth and clinical relevance, while operational complexities related to workflows, data, and procurement determine effective adoption. Stakeholders must approach sequencing as a systems challenge that spans instrument selection, validated consumables, interoperable analytics, and resilient supply chains. Emerging regulatory emphasis on validation and software integrity increases the premium on reproducible pipelines and documented quality management systems, and tariff-related procurement dynamics highlight the necessity of diversified sourcing and strategic vendor relationships.

Looking forward, the most successful organizations will combine technical excellence with operational foresight-investing in hybrid data infrastructures, workforce upskilling, and collaborative partnerships that accelerate validation and clinical integration. By focusing on validated workflows, robust data governance, and adaptive procurement strategies, leaders can translate sequencing capabilities into measurable research and clinical value. This conclusion underscores that the promise of genomic technologies will be realized not solely through isolated innovations, but through disciplined execution across the full sequencing ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next Generation Sequencing Market, by Technology

  • 8.1. Amplicon Sequencing
  • 8.2. Gene Panel Sequencing
  • 8.3. RNA Sequencing
  • 8.4. Targeted Sequencing
  • 8.5. Whole Exome Sequencing (WES)
  • 8.6. Whole Genome Sequencing (WGS)

9. Next Generation Sequencing Market, by Product Type

  • 9.1. Consumables Reagents
    • 9.1.1. Enzymes
    • 9.1.2. Kits
  • 9.2. Instruments
    • 9.2.1. Ancillary Instruments
    • 9.2.2. Sequencers
  • 9.3. Software Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Services

10. Next Generation Sequencing Market, by Workflow

  • 10.1. Data Analysis
    • 10.1.1. Alignment
    • 10.1.2. Annotation
    • 10.1.3. Variant Calling
  • 10.2. Data Storage
    • 10.2.1. Cloud Storage
    • 10.2.2. On-Premise Storage
  • 10.3. Sample Preparation
    • 10.3.1. Library Preparation
    • 10.3.2. Template Preparation
  • 10.4. Sequencing

11. Next Generation Sequencing Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Healthcare Diagnostic Laboratories
  • 11.3. Pharmaceutical Biotechnology Companies

12. Next Generation Sequencing Market, by Application

  • 12.1. Agrigenomics
  • 12.2. Carrier screening
  • 12.3. Epigenomics
  • 12.4. Forensic Genomics
  • 12.5. Genetic & Rare Diseases
  • 12.6. Infectious Diseases
  • 12.7. Neurogenomics
  • 12.8. Oncology
  • 12.9. Pharmacogenomics

13. Next Generation Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next Generation Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next Generation Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Next Generation Sequencing Market

17. China Next Generation Sequencing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 10x Genomics, Inc.
  • 18.6. Agilent Technologies, Inc.
  • 18.7. Azenta US, Inc.
  • 18.8. Becton, Dickinson and Company
  • 18.9. BGI Genomics Co., Ltd.
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. Danaher Corporation
  • 18.12. Eurofins Scientific SE
  • 18.13. F. Hoffmann-La Roche Ltd.
  • 18.14. Fulgent Genetics
  • 18.15. GenScript
  • 18.16. Hamilton Company
  • 18.17. Illumina, Inc.
  • 18.18. Invitae Corporation
  • 18.19. LGC Limited
  • 18.20. Macrogen Inc.
  • 18.21. Merck KGaA
  • 18.22. MGI Tech Co., Ltd.
  • 18.23. NeoGenomics Laboratories
  • 18.24. Novogene Co., Ltd.
  • 18.25. Oxford Nanopore Technologies Plc.
  • 18.26. Pacific Biosciences of California, Inc.
  • 18.27. QIAGEN N.V.
  • 18.28. Revvity
  • 18.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 244. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 278. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 280. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 282. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 283. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 292. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 295. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES NEX